Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FinlandBack to Finland

Clinical trials in Turku – page 19

297 clinical trials in Turku, Finland across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Turku at a glance
297
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

297 trials in Turku

Open in trial search

Plasma cell myeloma

Not recruiting

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Migraine

Not recruiting

Study on Rimegepant for Treating Migraine in Adults Who Cannot Use Triptans

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Migraine

Not recruiting

Study on Rimegepant for Preventing Migraines in Adults with Poor Response to Oral Preventive Medications

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Emphysema

Not recruiting

Study on Long-term Safety of Weekly Intravenous Alpha-1-Proteinase Inhibitor for Patients with Pulmonary Emphysema Due to Alpha-1-Antitrypsin Deficiency

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Alpha-1-Proteinase Inhibitor (Human)
  • Sponsor:Grifols Therapeutics LLC

Emphysema

Not recruiting

Study on the Effects of Alpha-1-Proteinase Inhibitor for Patients with Pulmonary Emphysema Due to Alpha-1 Antitrypsin Deficiency

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Alpha-1-Proteinase Inhibitor (Human)
  • Sponsor:Grifols Therapeutics LLC

Idiopathic pulmonary fibrosis+1

Not recruiting

Study on BI 1839100 for Reducing Cough in Patients with Idiopathic or Progressive Pulmonary Fibrosis

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bi 1839100
  • Sponsor:Boehringer Ingelheim Espana S.A.

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on Batoclimab for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Idiopathic pulmonary fibrosis

Not recruiting

Study on BI 1819479 to Improve Lung Function in Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bi 1819479
  • Sponsor:Boehringer Ingelheim Espana S.A.

Dupuytren's contracture

Not recruiting

Study on the Effectiveness of Collagenase, Percutaneous Needle Fasciotomy, and Limited Fasciectomy for Patients with Mild or Moderate Dupuytren's Contracture

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Collagenase
  • Sponsor:Pirkanmaan hyvinvointialue

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

Non-small cell lung cancer

Not recruiting

Study on JDQ443 and Docetaxel for Patients with Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Novartis Pharma AG

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Turku

What the registry says about research in the country

01 Respiratory Diseases

Comprehensive research focusing on respiratory infections including trials for influenza, RSV, and human metapneumovirus vaccines. Studies evaluate preventive measures for vulnerable populations.

  • Influenza vaccine development
  • RSV prevention in adults and infants
  • Viral respiratory infections

Multiple trials aim to enhance protection against seasonal respiratory illnesses in different age groups.

02 Infectious Diseases

Research centered on preventing and treating various infectious conditions, including studies of meningococcal vaccines and innovative approaches to viral infections.

  • Meningococcal prevention
  • Herpes Zoster vaccination
  • Yellow fever immunity

Studies focus on developing effective vaccination strategies for different age groups and populations.

03 Metabolic Disorders

Innovative trials examining treatments for obesity and diabetes, with particular attention to weight management therapies and metabolic health improvements.

  • Weight management interventions
  • Type 2 diabetes treatments
  • Combined therapeutic approaches

Research emphasizes lifestyle modifications alongside medical interventions.

04 Oncology

Advanced research in cancer treatment, particularly focusing on breast cancer and innovative therapeutic combinations for improved patient outcomes.

  • Breast cancer therapies
  • Leukemia treatments
  • Prostate cancer interventions

Studies evaluate both targeted therapies and combination treatments.

Back to FinlandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.